Literature DB >> 22302554

Age and diagnostic performance of Alzheimer disease CSF biomarkers.

N Mattsson1, E Rosén, O Hansson, N Andreasen, L Parnetti, M Jonsson, S-K Herukka, W M van der Flier, M A Blankenstein, M Ewers, K Rich, E Kaiser, M M Verbeek, M Olde Rikkert, M Tsolaki, E Mulugeta, D Aarsland, P J Visser, J Schröder, J Marcusson, M de Leon, H Hampel, P Scheltens, A Wallin, M Eriksdotter-Jönhagen, L Minthon, B Winblad, K Blennow, H Zetterberg.   

Abstract

OBJECTIVES: Core CSF changes in Alzheimer disease (AD) are decreased amyloid β(1-42), increased total tau, and increased phospho-tau, probably indicating amyloid plaque accumulation, axonal degeneration, and tangle pathology, respectively. These biomarkers identify AD already at the predementia stage, but their diagnostic performance might be affected by age-dependent increase of AD-type brain pathology in cognitively unaffected elderly.
METHODS: We investigated effects of age on the diagnostic performance of CSF biomarkers in a uniquely large multicenter study population, including a cross-sectional cohort of 529 patients with AD dementia (median age 71, range 43-89 years) and 304 controls (67, 44-91 years), and a longitudinal cohort of 750 subjects without dementia with mild cognitive impairment (69, 43-89 years) followed for at least 2 years, or until dementia diagnosis.
RESULTS: The specificities for subjects without AD and the areas under the receiver operating characteristics curves decreased with age. However, the positive predictive value for a combination of biomarkers remained stable, while the negative predictive value decreased only slightly in old subjects, as an effect of the high AD prevalence in older ages.
CONCLUSION: Although the diagnostic accuracies for AD decreased with age, the predictive values for a combination of biomarkers remained essentially stable. The findings highlight biomarker variability across ages, but support the use of CSF biomarkers for AD even in older populations.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22302554      PMCID: PMC3280049          DOI: 10.1212/WNL.0b013e3182477eed

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  39 in total

1.  The Oregon brain aging study: neuropathology accompanying healthy aging in the oldest old.

Authors:  M S Green; J A Kaye; M J Ball
Journal:  Neurology       Date:  2000-01-11       Impact factor: 9.910

2.  Neurofilament protein in cerebrospinal fluid: a marker of white matter changes.

Authors:  M Sjögren; M Blomberg; M Jonsson; L O Wahlund; A Edman; K Lind; L Rosengren; K Blennow; A Wallin
Journal:  J Neurosci Res       Date:  2001-11-01       Impact factor: 4.164

Review 3.  Research criteria for subcortical vascular dementia in clinical trials.

Authors:  T Erkinjuntti; D Inzitari; L Pantoni; A Wallin; P Scheltens; K Rockwood; G C Roman; H Chui; D W Desmond
Journal:  J Neural Transm Suppl       Date:  2000

Review 4.  Subcortical ischaemic vascular dementia.

Authors:  Gustavo C Román; Timo Erkinjuntti; Anders Wallin; Leonardo Pantoni; Helena C Chui
Journal:  Lancet Neurol       Date:  2002-11       Impact factor: 44.182

Review 5.  Mild cognitive impairment--beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.

Authors:  B Winblad; K Palmer; M Kivipelto; V Jelic; L Fratiglioni; L-O Wahlund; A Nordberg; L Bäckman; M Albert; O Almkvist; H Arai; H Basun; K Blennow; M de Leon; C DeCarli; T Erkinjuntti; E Giacobini; C Graff; J Hardy; C Jack; A Jorm; K Ritchie; C van Duijn; P Visser; R C Petersen
Journal:  J Intern Med       Date:  2004-09       Impact factor: 8.989

6.  CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age.

Authors:  Maartje I Kester; Marinus A Blankenstein; Femke H Bouwman; Evert J van Elk; Philip Scheltens; Wiesje M van der Flier
Journal:  J Alzheimers Dis       Date:  2009       Impact factor: 4.472

7.  The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease.

Authors:  Lidia Glodzik-Sobanska; Elizabeth Pirraglia; Miroslaw Brys; Susan de Santi; Lisa Mosconi; Kenneth E Rich; Remigiusz Switalski; Leslie Saint Louis; Martin J Sadowski; Frank Martiniuk; Pankaj Mehta; Domenico Pratico; Raymond P Zinkowski; Kaj Blennow; Mony J de Leon
Journal:  Neurobiol Aging       Date:  2007-10-24       Impact factor: 4.673

8.  Biomarkers in relation to cognitive reserve in patients with mild cognitive impairment--proof of concept.

Authors:  S Rolstad; A Nordlund; C Eckerström; M H Gustavsson; H Zetterberg; A Wallin
Journal:  Dement Geriatr Cogn Disord       Date:  2009-02-19       Impact factor: 2.959

Review 9.  Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; Jeroen G Lijmer; David Moher; Drummond Rennie; Henrica C W de Vet
Journal:  Clin Chem       Date:  2003-01       Impact factor: 8.327

10.  Prevalence of dementia disorders in the oldest-old: an autopsy study.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  Acta Neuropathol       Date:  2010-03-04       Impact factor: 17.088

View more
  61 in total

1.  Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease.

Authors:  Daniela Bertens; Dirk L Knol; Philip Scheltens; Pieter Jelle Visser
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

2.  [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging.

Authors:  Marta Marquié; Michael Siao Tick Chong; Alejandro Antón-Fernández; Eline E Verwer; Nil Sáez-Calveras; Avery C Meltzer; Prianca Ramanan; Ana C Amaral; Jose Gonzalez; Marc D Normandin; Matthew P Frosch; Teresa Gómez-Isla
Journal:  Acta Neuropathol       Date:  2017-06-13       Impact factor: 17.088

3.  Seed-competent high-molecular-weight tau species accumulates in the cerebrospinal fluid of Alzheimer's disease mouse model and human patients.

Authors:  Shuko Takeda; Caitlin Commins; Sarah L DeVos; Chloe K Nobuhara; Susanne Wegmann; Allyson D Roe; Isabel Costantino; Zhanyun Fan; Samantha B Nicholls; Alexis E Sherman; Ana T Trisini Lipsanopoulos; Clemens R Scherzer; George A Carlson; Rose Pitstick; Elaine R Peskind; Murray A Raskind; Ge Li; Thomas J Montine; Matthew P Frosch; Bradley T Hyman
Journal:  Ann Neurol       Date:  2016-08-03       Impact factor: 10.422

Review 4.  Nutritional strategies to optimise cognitive function in the aging brain.

Authors:  Devin Wahl; Victoria C Cogger; Samantha M Solon-Biet; Rosilene V R Waern; Rahul Gokarn; Tamara Pulpitel; Rafael de Cabo; Mark P Mattson; David Raubenheimer; Stephen J Simpson; David G Le Couteur
Journal:  Ageing Res Rev       Date:  2016-06-26       Impact factor: 10.895

5.  Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease.

Authors:  Rik Ossenkoppele; Niklas Mattsson; Charlotte E Teunissen; Frederik Barkhof; Yolande Pijnenburg; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici
Journal:  Neurobiol Aging       Date:  2015-04-25       Impact factor: 4.673

6.  Impact of Pre-Analytical Differences on Biomarkers in the ADNI and PPMI Studies: Implications in the Era of Classifying Disease Based on Biomarkers.

Authors:  Tessandra Stewart; Min Shi; Aanchal Mehrotra; Patrick Aro; David Soltys; Kathleen F Kerr; Cyrus P Zabetian; Elaine R Peskind; Peggy Taylor; Leslie M Shaw; John Q Trojanowski; Jing Zhang
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 7.  The association between late-life depression, mild cognitive impairment and dementia: is inflammation the missing link?

Authors:  Adriana P Hermida; William M McDonald; Kyle Steenland; Allan Levey
Journal:  Expert Rev Neurother       Date:  2012-11       Impact factor: 4.618

8.  The influence of cerebrospinal fluid (CSF) biomarkers on clinical dementia evaluations.

Authors:  Jonathan Gooblar; Brian D Carpenter; Mary A Coats; John C Morris; B Joy Snider
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

Review 9.  Olfactory Identification Deficits, Cognitive Decline, and Dementia in Older Adults.

Authors:  D P Devanand
Journal:  Am J Geriatr Psychiatry       Date:  2016-08-17       Impact factor: 4.105

Review 10.  Progress in Alzheimer's disease research in the last year.

Authors:  Daniela Galimberti; Elio Scarpini
Journal:  J Neurol       Date:  2013-04-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.